Neuraminidase inhibitors tied to lower death risk with H1N1

03/21/2014 | Healio (free registration) · Medscape (free registration)

An analysis of 78 studies involving more than 29,000 adults hospitalized for H1N1 influenza found that treatment with neuraminidase inhibitors was associated with a 19% lower mortality risk, regardless of the timing, compared with no treatment. Patients who received neuraminidase inhibitors within two days of illness onset were about half as likely to die as those treated later. The findings appear in The Lancet Respiratory Medicine.

View Full Article in:

Healio (free registration) · Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR